The Utility of Vascular Disrupting Agent in Ovarian Cancer - youtube video

video - Dr Monk (SGO)

Bradley J. Monk, MD, FACOG, FACS, Director, Division of Gynecologic Oncology, Vice Chair, Department of Obstetrics and Gynecology, University of Arizona Cancer Center-Phoenix, discusses a phase II trial presented at the 2015 SGO meeting. The trial evaluated bevacizumab in combination with the vascular disrupting agent fosbretabulin for the treatment of patients with recurrent ovarian, tubal, or peritoneal carcinoma. 

Bradley J. Monk, MD, FACOG, FACS, Director, Division of Gynecologic Oncology, Vice Chair, Department of Obstetrics and Gynecology, University of Arizona Cancer Center-Phoenix, discusses a phase II trial presented at the 2015 SGO meeting. The trial evaluated bevacizumab in combination with the vascular disrupting agent fosbretabulin for the treatment of patients with recurrent ovarian, tubal, or peritoneal carcinoma. - See more at: http://www.targetedonc.com/conference/sgo-2015/The-Utility-of-Vascular-Disrupting-Agent-in-Ovarian-Cancer#sthash.kvCvgnkw.dpuf

Bradley J. Monk, MD, FACOG, FACS, Director, Division of Gynecologic Oncology, Vice Chair, Department of Obstetrics and Gynecology, University of Arizona Cancer Center-Phoenix, discusses a phase II trial presented at the 2015 SGO meeting. The trial evaluated bevacizumab in combination with the vascular disrupting agent fosbretabulin for the treatment of patients with recurrent ovarian, tubal, or peritoneal carcinoma. - See more at: http://www.targetedonc.com/conference/sgo-2015/The-Utility-of-Vascular-Disrupting-Agent-in-Ovarian-Cancer#sthash.kvCvgnkw.dpuf